We previously examined the safety and immunogenicity of multiple vaccines administered to a military cohort, divided into two groups, the first composed of students at military schools, thus operating inside the national borders for at least 3 years, and the other formed of soldiers periodically engaged in a 9‐month‐long mission abroad (Lebanon). In the current study, we analyzed 112 individuals of this cohort, 50 pertaining to the first group and 62 to the second group, in order to examine the possible late appearance of side effects and to calculate the half‐life of the induced antibodies. Moreover, the possible involvement of B‐cell polyclonal activation as a pathogenetic mechanism for long term antibody persistence has even been explored. No late side effects, as far as autoimmunity and/or lymphoproliferation appearance, have been noticed. The long duration of the vaccine induced anti‐HAV antibodies has been confirmed, whereas the antibodies induced by tetravalent meningococcal polysaccharide vaccine have been found to persist above the threshold for putative protection for a longer time, and anti‐tetanus, diphtheria, and polio 1 and 3 for a shorter time than previously estimated. No signs of polyclonal B‐cell activation have been found, as a possible mechanism to understand the long antibody persistence.

Safety of multiple vaccinations and durability of vaccine‐induced antibodies in an Italian military cohort 5 years after immunization / Ferlito, C.; Visco, V.; Biselli, R.; Cattaruzza, M. S.; Carreras, G.; Salerno, G.; Lista, F.; Capobianchi, M. R.; Castilletti, C.; Lapa, D.; Antonelli, G.; Gentile, M.; Sorice, M.; Riitano, G.; Lucania, G.; Riccieri, V.; Mainiero, F.; Angeloni, A.; Lucarelli, M.; Ferraguti, G.; Autore, A.; Lastilla, M.; Salemi, S.; Biondo, M. I.; Picchianti-diamanti, A.; Caporuscio, S.; Teloni, R.; Mariotti, S.; Nisini, R.; D'Amelio, R.. - In: BIOMEDICINES. - ISSN 2227-9059. - 10:1(2022), pp. 1-15. [10.3390/biomedicines10010006]

Safety of multiple vaccinations and durability of vaccine‐induced antibodies in an Italian military cohort 5 years after immunization

Ferlito C.;Visco V.;Cattaruzza M. S.;Salerno G.;Antonelli G.;Gentile M.;Sorice M.;Riitano G.;Lucania G.;Riccieri V.;Mainiero F.;Angeloni A.;Lucarelli M.;Ferraguti G.;Biondo M. I.;Picchianti-diamanti A.;Caporuscio S.;D'amelio R.
2022

Abstract

We previously examined the safety and immunogenicity of multiple vaccines administered to a military cohort, divided into two groups, the first composed of students at military schools, thus operating inside the national borders for at least 3 years, and the other formed of soldiers periodically engaged in a 9‐month‐long mission abroad (Lebanon). In the current study, we analyzed 112 individuals of this cohort, 50 pertaining to the first group and 62 to the second group, in order to examine the possible late appearance of side effects and to calculate the half‐life of the induced antibodies. Moreover, the possible involvement of B‐cell polyclonal activation as a pathogenetic mechanism for long term antibody persistence has even been explored. No late side effects, as far as autoimmunity and/or lymphoproliferation appearance, have been noticed. The long duration of the vaccine induced anti‐HAV antibodies has been confirmed, whereas the antibodies induced by tetravalent meningococcal polysaccharide vaccine have been found to persist above the threshold for putative protection for a longer time, and anti‐tetanus, diphtheria, and polio 1 and 3 for a shorter time than previously estimated. No signs of polyclonal B‐cell activation have been found, as a possible mechanism to understand the long antibody persistence.
2022
antibody durability; antibody persistence; B‐cell polyclonal activation; safety; vaccines
01 Pubblicazione su rivista::01a Articolo in rivista
Safety of multiple vaccinations and durability of vaccine‐induced antibodies in an Italian military cohort 5 years after immunization / Ferlito, C.; Visco, V.; Biselli, R.; Cattaruzza, M. S.; Carreras, G.; Salerno, G.; Lista, F.; Capobianchi, M. R.; Castilletti, C.; Lapa, D.; Antonelli, G.; Gentile, M.; Sorice, M.; Riitano, G.; Lucania, G.; Riccieri, V.; Mainiero, F.; Angeloni, A.; Lucarelli, M.; Ferraguti, G.; Autore, A.; Lastilla, M.; Salemi, S.; Biondo, M. I.; Picchianti-diamanti, A.; Caporuscio, S.; Teloni, R.; Mariotti, S.; Nisini, R.; D'Amelio, R.. - In: BIOMEDICINES. - ISSN 2227-9059. - 10:1(2022), pp. 1-15. [10.3390/biomedicines10010006]
File allegati a questo prodotto
File Dimensione Formato  
Ferlito_Safety_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 288.44 kB
Formato Adobe PDF
288.44 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1607852
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact